Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

CNBC put the number on it: $106 billion. That is total biotech M&A in 2026 through early June, and it puts the year on pace to be the strongest since before the pandemic. The article quoted EY partner Jessica Kumar and Forbion's Sander Slootweg describing a market where companies are "buying stuff like it's going out of fashion." The drivers we have tracked all year are now consensus: patent cliff urgency ($320B in revenue exposure by 2030), deep cash reserves, attractive biotech valuations, and a historically productive China licensing pipeline. CNBC noted that AstraZeneca, Pfizer, and BMS have each committed more than $16B to Chinese partnerships since the start of 2025. Forbion's Luneborg said "clearly the interest in buying assets out of China is not fading" despite COINS Act pressure. Meanwhile, the Supreme Court's Vascepa ruling is a significant IP precedent. The Court sided with Hikma's generic, which means Amarin's patent estate could not block competition. For pharma companies relying on patent thickets to extend exclusivity (AbbVie's Rinvoq 2037 settlement, for example), the ruling is a reminder that patent strategy has limits. And Gilead's post-Arcellx layoffs, 192 of 220 employees, are the starkest illustration of what M&A integration actually looks like on the ground. 👉 Read Full Analysis

🔮 What To Watch

📊 M&A & Capital Markets

Biotech M&A Hits $106B, on Pace for Best Year Since Pre-COVID

CNBC reported on June 4 that biotech dealmaking has reached $106B in 2026, putting the year on track for the strongest M&A performance since before the pandemic. The article noted several key dynamics:

This aligns with the Reuters $84B Q1 figure (Dealogic) and BioWorld's $93B through April. The $106B CNBC figure covers a slightly different time period and methodology. Regardless of the exact count, 2026 is a historic year for biopharma dealmaking.

🔬 IP & Patent Law

Supreme Court Sides with Hikma on Vascepa, Amarin Loses Patent Fight

The U.S. Supreme Court ruled that Hikma Pharmaceuticals' generic version of Amarin's Vascepa (icosapent ethyl) does not infringe patents held by the Irish company, according to Fierce Pharma. The ruling opens the door for generic competition in the cardiovascular fish oil market and sets a precedent for how method-of-treatment patents are evaluated in generic challenges. For pharma companies that rely on patent estates to extend branded drug exclusivity, the ruling narrows the enforceability of certain patent claims against generic entrants.

🏢 Corporate & Business Developments

Lilly Medicare Deal Restores Foundayo and Zepbound Coverage LLY

BioPharma Dive reported that Eli Lilly reached a Medicare agreement that includes coverage for Foundayo and restores coverage for Zepbound, "erasing what had been a commercial edge for rival Novo Nordisk." The deal means both Foundayo (oral GLP-1) and Zepbound (injectable GLP-1/GIP) will be available through the Medicare GLP-1 Bridge program launching July 1 at a $50 copay. This levels the competitive playing field between Lilly and Novo in the Medicare population.

Gilead Cuts 87% of Arcellx Workforce Post-Acquisition GILD

Gilead is laying off 192 of approximately 220 Arcellx employees following the close of its $7.8B acquisition, according to BioSpace WARN notices. The cuts include 108 at Arcellx's Redwood City, California headquarters (effective June 30) and 84 in Rockville, Maryland (through April 2027). Arcellx's lead program anito-cel for multiple myeloma is now fully within Gilead's organization. The scale of the cuts, 87% of total staff, illustrates the operational reality of large pharma acquiring small biotechs: the science transfers, but most of the people do not.

📋 The Week in Review

📅 The Week Ahead

CNBC's $106B figure for 2026 M&A through early June puts the year on pace for approximately $200B to $250B full-year, consistent with earlier projections from Reuters ($250B, Dealogic data) and Jefferies ($172B, narrower methodology). The key drivers remain:

Patent cliff: $320B in branded drug revenue faces LOE by 2030. Companies must replace declining franchises.

China pipeline: AstraZeneca, Pfizer, and BMS have each committed >$16B to Chinese partnerships since early 2025. The licensing wave shows no signs of slowing despite COINS Act pressure.

Capital availability: Lilly alone has deployed $30B+ across 12 deals. Gilead committed $15B in Q1. Merck, AbbVie, Novartis, and UCB are all active.

Biotech valuations: Despite the recovery from 2022-2024 lows, biotech valuations remain below 2021 peaks, making clinical-stage assets attractive relative to their data quality.

Forbion's Luneborg: "I don't think pharma is panic buying." The data suggest she is right. The deals are strategic, diversified across modalities and therapeutic areas, and increasingly backed by Phase 3 data. This is not a bubble. It is a structural realignment of the industry.

💊 Vascepa: The Patent Strategy Lesson

The SCOTUS Vascepa ruling is a warning for pharma companies that rely on method-of-treatment patents to extend exclusivity. Amarin's patent estate attempted to block generic icosapent ethyl by claiming the method of use (reducing cardiovascular risk in patients with elevated triglycerides) was patented separately from the compound itself. The Court disagreed.

The implication: method-of-treatment patents are harder to enforce against generics than composition-of-matter patents. Companies like AbbVie (Humira patent thicket, Rinvoq 2037 settlement) have used settlements to avoid testing their patent estates in court. The Vascepa ruling suggests that if those cases had gone to trial, some patent claims might not have held.

For BD teams: when evaluating the durability of branded drug exclusivity, discount method-of-treatment patents relative to composition-of-matter patents. The SCOTUS precedent makes the latter more defensible.

📊 The Integration Reality

Gilead paid $7.8B for Arcellx. Within weeks of closing, 87% of Arcellx's 220 employees were laid off. The science (anito-cel for multiple myeloma) transferred. The people did not.

This is not unusual. When large pharma acquires small biotech, the acquirer typically retains the lead program, a handful of key scientists, and the intellectual property. Everything else is absorbed into the acquirer's existing infrastructure. The Arcellx cuts are on the higher end (87% vs. a more typical 50-70%), but the pattern is consistent across the industry.

For biotech employees at acquisition targets: the acquisition premium goes to shareholders. The operational integration typically means significant workforce reduction. For investors: integration risk is real. The 87% cut means Gilead is betting it can advance anito-cel without the team that built it. That is a bet on Gilead's internal capabilities, not Arcellx's.

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →